一项具有里程碑意义的基因组检测技术近日公布，该技术能够更精准地评估乳腺癌患者是否需要接受化疗，有望使数百万患者免于不必要的化疗痛苦。

传统上，医生在手术后会建议大多数乳腺癌患者接受化疗以降低复发风险。然而，研究表明相当一部分患者实际上并不需要化疗即可保持良好的预后。新的基因检测方法通过分析肿瘤样本中特定基因的表达模式，能够更准确地预测哪些患者属于低复发风险群体。

临床试验数据显示，使用该技术后，约30%至40%原本会被建议接受化疗的患者可以安全地避免这一治疗。这不仅大幅减少了患者的副作用和经济负担，也节省了医疗资源。

肿瘤学专家表示，这项技术代表了精准医疗在肿瘤领域的重大进步。通过基因组学手段，医生可以为每位患者制定更加个性化的治疗方案，避免"一刀切"的治疗模式。

目前，该技术正在多个国家申请医疗监管审批，预计将在未来一年内逐步投入临床应用。

Breakthrough Genomic Test Could Spare Millions of Breast Cancer Patients from Chemotherapy

A landmark genomic testing technology has been announced that could more accurately assess which breast cancer patients need chemotherapy, potentially sparing millions from unnecessary treatment.

Traditionally, doctors have recommended chemotherapy for most breast cancer patients after surgery to reduce recurrence risk. However, studies show a significant portion of patients actually do not need chemotherapy to maintain good outcomes. The new genomic test analyzes expression patterns of specific genes in tumor samples to more accurately predict which patients fall into the low-recurrence-risk category.

Clinical trial data shows that using this technology, approximately 30% to 40% of patients who would otherwise be recommended for chemotherapy can safely avoid it. This significantly reduces patients’ side effects and financial burden while conserving medical resources.

Oncology experts say this technology represents a major advance in precision medicine for cancer. Through genomic approaches, doctors can develop more personalized treatment plans for each patient, moving away from a one-size-fits-all treatment model.

The test is currently seeking regulatory approval in multiple countries and is expected to enter clinical use within the next year.

据 BBC 科技频道报道，加州总检察长已对 23andMe 的继承公司提起诉讼，指控其在 2023 年大规模数据泄露事件中未能妥善保护用户基因数据。该事件导致数百万用户的敏感遗传信息被暴露。

23andMe 曾因基因检测服务广受欢迎，但近年来面临财务困境和业务重组。此次诉讼凸显了基因数据保护领域的监管趋严趋势。加州总检察长办公室表示，基因数据属于高度敏感的个人信息，企业必须承担最高的安全保护义务。